Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy

This real-world study in Italy tracks patients with moderate-to-severe plaque psoriasis (a chronic skin condition that causes red, scaly patches) who have recently started a new treatment called deucravacitinib, to see how well it works and how well patients tolerate it in everyday clinical practice. **You may be eligible if...** - You have moderate to severe plaque psoriasis - You started deucravacitinib treatment 4 to 8 weeks ago as part of your regular care - Your treatment meets Italian national reimbursement guidelines - You have provided written informed consent **You may NOT be eligible if...** - You have not yet started deucravacitinib or started it outside the required time window - You do not meet the national reimbursement criteria for this medication Talk to your doctor to see if this trial is right for you.